von Bubnoff N - Search Results

1

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. von Bubnoff N, et al. Blood. 2005 Feb 15;105(4):1652-9. doi: 10.1182/blood-2004-06-2445. Epub 2004 Sep 30. Blood. 2005. PMID: 15459011 Free article.

2

Near complete remission of an inoperable pancreatic acinar cell carcinoma after BRAF-/MEK-inhibitor treatment-A case report and review of the literature.

von Fritsch L, von Bubnoff N, Weber K, Kirfel J, Schreiber C, Keck T, Wellner U. von Fritsch L, et al. Among authors: von bubnoff n. Genes Chromosomes Cancer. 2024 Feb;63(2):e23222. doi: 10.1002/gcc.23222. Genes Chromosomes Cancer. 2024. PMID: 38340027 Review.

3

Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast.

von Bubnoff N, Sandherr M, Schneller F, Peschel C. von Bubnoff N, et al. Am J Clin Oncol. 2000 Feb;23(1):74-7. doi: 10.1097/00000421-200002000-00021. Am J Clin Oncol. 2000. PMID: 10683084

4

Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose.

Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, Avril N. Sandherr M, et al. Among authors: von schilling c, von bubnoff n. Ann Oncol. 2001 May;12(5):719-22. doi: 10.1023/a:1011136324038. Ann Oncol. 2001. PMID: 11432634 Free article.

5

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

von Bubnoff N, Schneller F, Peschel C, Duyster J. von Bubnoff N, et al. Lancet. 2002 Feb 9;359(9305):487-91. doi: 10.1016/S0140-6736(02)07679-1. Lancet. 2002. PMID: 11853795

6

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.

von Bubnoff N, Peschel C, Duyster J. von Bubnoff N, et al. Leukemia. 2003 May;17(5):829-38. doi: 10.1038/sj.leu.2402889. Leukemia. 2003. PMID: 12750693 Review.

7

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.

von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. von Bubnoff N, et al. Cancer Res. 2003 Oct 1;63(19):6395-404. Cancer Res. 2003. PMID: 14559829

8

[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].

Von Bubnoff N, Peschel C, Duyster J. Von Bubnoff N, et al. Dtsch Med Wochenschr. 2004 Oct 1;129(40):2100-3. doi: 10.1055/s-2004-831851. Dtsch Med Wochenschr. 2004. PMID: 15455301 German.

9

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia.

von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. von Bubnoff N, et al. Leukemia. 2005 Feb;19(2):286-7. doi: 10.1038/sj.leu.2403600. Leukemia. 2005. PMID: 15618966 No abstract available.

10

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.

von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J. von Bubnoff N, et al. Cell Cycle. 2005 Mar;4(3):400-6. doi: 10.4161/cc.4.3.1560. Epub 2005 Mar 25. Cell Cycle. 2005. PMID: 15738656 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

160 results

Search Page

Filters